Peptide FAQ — honest answers, labeled evidence

Short answer: unknown. The BPC-157 safety record looks clean in rats — no lethal dose established, no organ toxicity, no HPA-axis suppression in rodent studies (🐀 animal). But there is no published large-scale human safety trial. A Phase II trial for ulcerative colitis was conducted under the code PL 14736, but detailed peer-reviewed results have not been made public. It is not approved by the FDA, EMA or any regulator, and WADA added it to the Prohibited List in 2022. Theoretical concerns remain around long-term VEGFR2-mediated angiogenesis and occult tumor vascularization. See our full BPC-157 review.

Several. Approved peptide drugs include insulin analogues, semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), tirzepatide (Mounjaro, Zepbound), octreotide, teriparatide (Forteo), leuprolide and many others. None of the "research peptides" commonly discussed online — BPC-157, TB-500, Ipamorelin, CJC-1295, Epitalon, GHK-Cu as an injectable, Selank, Semax, Kisspeptin-10 — are FDA approved. Retatrutide is in Phase III trials but not yet approved (as of early 2026).

It means the compound is sold for laboratory research, not for human consumption. Vendors use this label to stay outside drug regulations. In practice: no manufacturing quality oversight comparable to a GMP pharmaceutical, no sterility guarantee, no dose verification, and no FDA approval for any human indication. Buying something marked "research use only" and injecting it is a personal risk decision made without the normal safety framework of approved medicine.

Drug development is expensive. Animal studies are the first step — they're cheaper, faster, and ethically permissible for early safety and efficacy signals. Moving to human trials requires millions of dollars, regulatory submissions (IND in the US), and sponsors willing to invest. Most research peptides never attract that investment because they are unpatentable natural sequences with limited commercial incentive. Rodent data tell us a mechanism might work, but they do not prove it works in humans — species differences in pharmacokinetics, dosing, and receptor biology are often large.

Depends on the peptide. Most are destroyed by stomach acid and digestive enzymes, which is why research doses are usually injected subcutaneously. Exceptions: BPC-157 is unusually stable in gastric acid and has shown effects after oral dosing in animal studies (🐀 animal). Semaglutide has an oral formulation (Rybelsus) that uses an absorption enhancer (SNAC). Semax and Selank are often given as intranasal sprays because the nasal mucosa can absorb small peptides directly. For most other research peptides, oral bioavailability is near zero.

No. Topical skincare products labeled "copper peptides" typically contain GHK-Cu at low concentrations in a cream or serum and are cosmetic products — the evidence for modest skin benefits is actually reasonable (👥 human). Injected GHK-Cu for hair growth or systemic wound healing is a different use case, is not FDA approved, and the human evidence for those uses is much weaker.

DAC stands for Drug Affinity Complex. CJC-1295 with DAC contains a maleimide group that binds to albumin, extending half-life to roughly 6–8 days. CJC-1295 without DAC (also called modified GRF 1-29) has a half-life closer to 30 minutes. The "with DAC" version gives a sustained GH elevation; the "no DAC" version gives a pulse. Neither is FDA approved.

No reliable answer for research peptides. Some peptides stimulate angiogenesis (BPC-157) or cellular proliferation (IGF-1, GH secretagogues), which is theoretically concerning in the presence of existing tumors but has not been shown to initiate cancer. Long-term human safety data simply do not exist for most research peptides. For approved peptide drugs like GLP-1 agonists, large long-term trials have not found a clear cancer signal in humans despite thyroid C-cell tumor concerns observed in rodent studies.

Bacteriostatic water is sterile water containing 0.9% benzyl alcohol as a preservative. The benzyl alcohol inhibits bacterial growth, allowing the vial to be used for up to 28 days after first puncture. It is the standard reconstitution fluid used in peptide research literature. Plain sterile water should be discarded after a single use.

In Phase II trials, retatrutide produced larger mean weight reductions than semaglutide has in its own trials — roughly 24% at 48 weeks at the highest dose (👥 human). But these are cross-trial comparisons, not head-to-head, so they must be interpreted cautiously. Retatrutide is a triple agonist (GLP-1, GIP, glucagon) vs semaglutide's single GLP-1 action. Retatrutide is not yet approved. See the full retatrutide vs semaglutide comparison.

Neither shows classical dependence or withdrawal in the published Russian literature. Selank is a synthetic tuftsin analog with reported anxiolytic effects without benzodiazepine-style sedation or tolerance (👥 human). Semax is an ACTH-derived heptapeptide used as a cognitive/anxiolytic nasal spray (👥 human, mostly Russian studies). Neither is approved outside Russia, and Western replication of the results is limited.

It depends on the peptide and your country. In most Western jurisdictions, non-approved research peptides sit in a grey zone: legal to sell labeled "for research use only" but illegal to market, prescribe, or import for human consumption. Approved peptide drugs require a prescription. This site does not provide sourcing or purchasing advice.

Usually not. Collagen peptides are the main exception — they are broken into di- and tri-peptides in the gut and some fragments appear in circulation, which is plausibly why oral collagen has modest evidence for skin and joint outcomes (👥 human). Most other peptides are digested into component amino acids and lose their sequence-specific activity. Oral "BPC-157 capsules" are the exception supported by some rodent data, but human oral bioavailability is unconfirmed.

Peptides are short chains of amino acids. SARMs (Selective Androgen Receptor Modulators) are small non-peptide molecules that bind the androgen receptor — chemically closer to steroids than to peptides. They are frequently lumped together in "biohacker" contexts but are structurally and pharmacologically unrelated. SARMs are not peptides.

PubMed (pubmed.ncbi.nlm.nih.gov) is the primary source for peer-reviewed peptide research. ClinicalTrials.gov lists ongoing human trials. Our news page tracks major human-trial milestones in plain language. Avoid YouTube "biohacker" channels as primary sources — they often misrepresent animal data as human evidence.